Cardiac Biotech Solutions Activates China Production Pipeline for MyCardia AT and Moves into Final NMPA Submission Phase

Regulated manufacturing, hospital field trials, and regulatory filings now underway with Ebulent Medical in ShenzhenLAS VEGAS, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Cardiac Biotech Solutions, Inc. (OTCID: CBSC) (“CBSC” or the “Company”), a designer, manufacturer and distributor of non-invasive ambulatory cardiac monitoring products, today provided an update on the execution of its China market entry plan for its MyCardia AT cardiac event monitoring device. The Company has formally initiated manufacturing and re ...